NCT02358889 - Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Choroidal NeovascularizationAge-related Macular Degeneration

Interventions

BIOLOGICAL

hI-con1

Intravitreal injection of hI-con1 0.3 mg

BIOLOGICAL

ranibizumab

Intravitreal injection of ranibizumab 0.5 mg

OTHER

Sham injection

No injection is given, a needleless syringe is used to mimic an injection.

Trial Locations (48)

11223

Brooklyn

11788

Hauppauge

13224

Syracuse

19006

Huntingdon Valley

19107

Philadelphia

21209

Baltimore

29169

West Columbia

30909

Augusta

32405

Panama City

33426

Boynton Beach

33907

Fort Myers

Winter Haven

34233

Sarasota

34994

Stuart

37660

Kingsport

42001

Paducah

48072

Detroit

48073

Royal Oak

48322

West Bloomfield

49202

Jackson

53705

Madison

55435

Minneapolis

77030

Houston

77384

The Woodlands

78240

San Antonio

78503

McAllen

78705

Austin

79606

Abilene

80401

Golden

84107

Salt Lake City

85020

Phoenix

85021

Phoenix

89144

Las Vegas

90211

Beverly Hills

91007

Arcadia

91203

Glendale

92260

Palm Desert

92653

Laguna Hills

92705

Santa Ana

94040

Mountain View

94109

San Francisco

94303

Palo Alto

95008

Campbell

97210

Portland

97520

Ashland

98383

Silverdale

02111

Boston

07003

Bloomfield